electroCore
electroCore's revenue rose 27.2% to $32 million in fiscal 2025. Its operating margin was −41.1%, up from −48.3% a year earlier. Free cash flow was −$8 million. The diluted share count rose 13.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
electroCore lost money in fiscal 2025: a net loss of $14 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 35 | 18 | 10 | 12 | 12 |
| Debt incl. finance leases | — | — | — | — | 8 |
| Net debt (negative means net cash) | — | — | — | — | −4 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −2,004.3x | −5,718.5x | −1,482.2x | −661.0x | −882.8x |
| Current ratio | 6.8x | 3.0x | 1.8x | 1.8x | 1.4x |
| Quick ratio | 6.6x | 2.7x | 1.5x | 1.6x | 1.2x |
Cash flow
Projections
Project electroCore's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $176,158 of electroCore shares on the open market, and 2 insiders sold $933,001.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 17, 2026 | Michael FoxSee Remarks | Bought | 2,500 | $5.25 | $13,116 | Form 4 |
| Sep 14, 2026 | Thomas J. ErricoDirector | Bought | 5,000 | $9.82 | $49,100 | Form 4 |
| Aug 25, 2026 | Joshua S. LevCFO and Interim President | Sold | 3,000 | $9.36 | $28,080 | Form 4 |
| Aug 24, 2026 | Joshua S. LevCFO and Interim President | Sold | 5,000 | $9.88 | $49,400 | Form 4 |
| Aug 21, 2026 | Joshua S. LevCFO and Interim President | Sold | 12,000 | $10.22 | $122,640 | Form 4 |
| Aug 13, 2026 | Thomas J. ErricoDirector | Bought | 5,000 | $9.85 | $49,250 | Form 4 |
| May 28, 2026 | Joshua S. LevCFO and Interim President | Sold | 6,667 | $9.00 | $60,003 | Form 4 |
| May 22, 2026 | Joshua S. LevCFO and Interim President | Sold | 3,000 | $6.50 | $19,500 | Form 4 |
| May 21, 2026 | Thomas J. ErricoDirector | Bought | 9,992 | $5.99 | $59,852 | Form 4 |
| Apr 23, 2026 | Daniel S GoldbergerFormer Officer & Director | Sold | 80,000 | $6.80 | $544,000 | Form 4 |
| Apr 10, 2026 | Daniel S GoldbergerFormer Officer and Director | Sold | 16,072 | $6.02 | $96,753 | Form 4 |
| Dec 4, 2025 | Joshua S. LevChief Financial Officer | Sold | 2,500 | $5.05 | $12,625 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −6.2% | — | 1.4% |
| Altman Z'' | −38.07 | −29.29 | −36.67 |
| Accruals ratio | −20.4% | −27.0% | −29.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put electroCore side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| electroCore | FY25 | 27.2% | −41.1% | −25.8% | — | — | — | |
| Stereotaxis | FY25 | 20.3% | −68.3% | −42.5% | — | — | — | Compare |
| Precision Optics Corporation | FY26 | 65.2% | −11.1% | −6.3% | −22.8% | — | 5 | Compare |
| Orchestra BioMed | FY25 | 1,169.2% | −154.7% | −147.7% | — | — | 5 | Compare |
| Senseonics | FY25 | 56.9% | −193.8% | −170.9% | — | — | 4 | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 1 | 1 | 2 | 4 | 6 | 9 | 16 | 25 | 32 |
| Revenue growth | — | 22.4% | 140.7% | 46.2% | 55.9% | 57.6% | 86.6% | 57.1% | 27.2% |
| Gross profit | 0 | 0 | 1 | 2 | 4 | 7 | 13 | 21 | 28 |
| Research and development | 8 | 12 | 10 | 4 | 2 | 6 | 5 | 2 | — |
| Operating income | −26 | −55 | −46 | −25 | −20 | −23 | −19 | −12 | −13 |
| Net income | −36 | −56 | −45 | −24 | −17 | −22 | −19 | −12 | −14 |
| Diluted EPS (US$) | — | −17.85 | −23.10 | −9.00 | −4.36 | −4.69 | −3.42 | −1.59 | −1.65 |
| Diluted shares (millions) | — | 2 | 2 | 3 | 4 | 5 | 6 | 8 | 8 |
| Cash flow | |||||||||
| Cash from operations | −25 | −47 | −45 | −20 | −14 | −17 | −15 | −7 | −8 |
| Capital expenditure | 0 | 0 | 0 | — | — | — | 0 | — | 0 |
| Free cash flow | −25 | −47 | −45 | — | — | — | −15 | — | −8 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 8 | 4 | 3 | 3 | 3 | 2 | 2 | 2 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | 37 | 69 | 24 | 23 | 35 | 18 | 10 | 12 | 12 |
| Debt incl. finance leases | — | — | — | 1 | — | — | — | — | 8 |
| Total assets | 39 | 74 | 36 | 32 | 43 | 25 | 16 | 20 | 19 |
| Total liabilities | 6 | 7 | 11 | 8 | 6 | 8 | 9 | 13 | 20 |
| Shareholders' equity | −90 | 66 | 24 | 23 | 37 | 17 | 7 | 8 | −2 |
| Margins and ratios | |||||||||
| Gross margin | 36.1% | 41.7% | 51.6% | 50.3% | 74.6% | 81.2% | 82.5% | 85.0% | 86.8% |
| Operating margin | −3,160.3% | −5,494.1% | −1,928.2% | −707.9% | −367.7% | −266.2% | −120.2% | −48.3% | −41.1% |
| Net margin | −4,410.9% | −5,621.7% | −1,888.8% | −672.5% | −315.9% | −257.9% | −117.5% | −47.2% | −43.6% |
| Free cash flow margin | −3,140.2% | −4,772.6% | −1,888.3% | — | — | — | −92.8% | — | −25.8% |
| Rule of 40 (growth + FCF margin) | — | −4,750.2% | −1,747.6% | — | — | — | −6.2% | — | 1.4% |
| Return on capital | — | — | — | — | — | — | — | — | — |
| Return on equity | — | — | −100.5% | −99.5% | −57.7% | −82.5% | −153.6% | −158.6% | −478.7% |
| Return on assets | — | −99.0% | −82.9% | −70.2% | −46.3% | −65.6% | −92.2% | −65.0% | −71.4% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — |